Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
--------------------------------
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the year ended December 31, 2002
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File No. 0-12991
-------
LANGER, INC.
---------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 11-2239561
-------------- ---------------------
(State or other jurisdiction (I.R.S. employer iden-
of incorporation or tification number)
organization)
450 COMMACK ROAD, DEER PARK, NEW YORK 11729-4510
---------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (631) 667-1200
--------------
Securities registered pursuant to Section 12(b) of the Act: NONE
----
Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK, PAR VALUE $.02 PER SHARE
--------------------------------------
Title of Class
* * * * * * * * * * *
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
YES [X] NO [ ]
1
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. ( )
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act):
Yes [ ] No [X]
As of March 25, 2003, the aggregate market value of voting stock held by
non-affiliates of the registrant was $8,654,462, as computed by reference to the
closing price of such common stock ($3.10) multiplied by the number of shares of
voting stock outstanding on March 25, 2003 held by non-affiliates (2,791,762
shares). Exclusion of shares from the calculation of aggregate market value does
not signify that a holder of any such shares is an "affiliate" of the Company.
Indicate the number of shares outstanding of each of the registrant's classes of
common stock as of March 25, 2003.
CLASS OF COMMON STOCK OUTSTANDING AT MARCH 25, 2003
--------------------- -----------------------------
Common Stock, par value 4,444,355 shares
$.02 per share
DOCUMENTS INCORPORATED BY REFERENCE
-----------------------------------
The information required by Part III of this report is incorporated herein by
reference to the Company's proxy statement for the 2003 annual meeting of the
registrant's stockholders or amendment hereto which will be filed not later than
120 days after the end of the fiscal year covered by this report.
2
LANGER, INC.
FORM 10-K
TABLE OF CONTENTS
PAGE
PART I
ITEM 1. BUSINESS............................................................4
ITEM 2. PROPERTIES.........................................................11
ITEM 3. LEGAL PROCEEDINGS..................................................11
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS................11
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS................................................12
ITEM 6. SELECTED FINANCIAL DATA............................................14
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS................................15
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK........................................................22
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA........................23
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND DISCLOSURE..........................................47
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY....................47
ITEM 11. EXECUTIVE COMPENSATION.............................................47
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT.....................................................47
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.....................47
PART IV
ITEM 14. CONTROLS AND PROCEDURES............................................48
ITEM 15. EXHIBITS, FINANCIAL STATEMENTS, FINANCIAL STATEMENT
SCHEDULES, AND REPORTS ON FORM 8-K.................................48
SIGNATURES...................................................................52
3
PART I
ITEM 1. BUSINESS
- ----------------
Langer, Inc. (the "Company or "we") is a leading orthotics products company
specializing in designing, manufacturing, distributing and marketing high
quality foot and gait-related biomechanical products. The Company's diversified
range of products is comprised of (i) custom orthotic devices ordered by
licensed medical practitioners and (ii) distribution of pre-fabricated
orthopedic rehabilitation and recovery devices and related devices sold to a
patient by licensed medical practitioners.
The Company's custom orthotic devices are contoured molds, purchased by a
licensed medical practitioner for a patient, which are worn in the shoe to
correct biomechanical foot and postural disorders in patients which often result
in pain or discomfort, or otherwise impede an individual's ability to maintain a
normal gait. The Company also provides custom orthotics which support or control
the ankle region (ankle foot orthosis).
The Company's distributed products are purchased by licensed medical
practitioners for resale to patients and consist of prefabricated products for
the foot and lower extremities and a selection of footware. These products,
which supplement our custom orthotic devices, consist of shoe inserts, ankle
braces, compression hose and socks, and therapeutic shoes and sneakers. In
addition, we distribute PPT(R) to manufacturers who incorporate PPT(R) into
their products. PPT(R) is a soft tissue cushioning material made from medical
grade urethane produced in laminated sheet form, molded insoles, and components
for orthotic devices.
INDUSTRY BACKGROUND
- -------------------
The Company competes in the portion of the orthopedic rehabilitation and
recovery market segment which manufactures, markets, sells, and distributes
orthopedic products and retail orthopedic products. The Company estimates that
global orthopedic rehabilitation and recovery market revenues exceed $8 billion
annually. The Company believes the estimated revenues of the orthopedic products
and retail orthopedic products markets in which we compete exceed $2 billion
annually.
The Company believes the growth of these markets is being driven by strong
demographic and other trends, including:
o an aging population who historically have required a higher than
average percentage of orthotic and orthopedic products and services
than the general population;
o a growth rate of persons 65 and older which is nearly triple that of
the balance of the population;
o an increased participation in exercise, sports, and other physical
activities by all age groups which has directly led to increased
orthopedic related strains and injuries requiring orthotic and related
products;
o a growing awareness of the importance of prevention and rehabilitation
of orthopedic injuries; and
o an industry-wide consolidation leading to greater marketing and sales
resources.
Podiatrists in the United States are the largest single source of custom foot
orthotic products. In the United States, Medicare and most health care
organizations that provide coverage for foot orthotics require a podiatrist or
other licensed doctor to write a prescription and indicate the diagnosis and
need for the custom orthotic. Due to the nature of this reimbursement
environment, little effort is directed at marketing to the end user of the
product. Instead, custom orthotics manufacturers market and distribute their
foot orthotic laboratory services to licensed medical practitioners, including
podiatrists, chiropractors, orthopedic surgeons, orthotists/prosthetists,
physical therapists, and athletic trainers.
4
While the market for custom orthotics outside the United States is similar in
size to the United States market, prefabricated orthotic devices are generally
preferred in Europe due to reimbursement policies in several European countries.
The Company currently markets our products in Canada and the United Kingdom,
markets where favorable national reimbursement and payment structures prevail.
The Company also markets our products in thirty other countries.
GROWTH STRATEGY
- ---------------
The Company expects the demand for orthotic products will continue to grow. We
plan to execute our growth strategy primarily through internal expansion of our
existing businesses and through strategic acquisitions of businesses offering
complementary services, markets, and customer bases. The following elements
define our growth strategy:
Pursue Strategic Acquisitions. The foot orthotic products industry is highly
fragmented and characterized primarily by smaller, geographically restricted
manufacturers. As a result, we selectively pursue acquisitions that complement
and expand our product offerings and provide access to new geographic markets
and new medical practitioner relationships.
Expand Distribution Network and Product Offerings. The Company believes that a
broader product line will encourage additional licensed medical practitioners to
order our custom orthotics products and will enhance our brand appeal with
licensed medical practitioners and patients. We will seek to continue to expand
our range of products through the acquisition of niche product manufacturers and
by investing in the development of new and enhanced products which complement
our existing offerings.
Broaden Product Offerings to Licensed Medical Practitioner and Customer Base.
The Company will seek to increase penetration of our existing licensed medical
practitioner and customer base with sales of additional products. We also intend
to increase customer satisfaction and strengthen our customer relationships
through expanded product offerings.
Research and Development. The Company will continue to conduct research and
development to conceive and evaluate new or alternative orthotics products and
services. We believe that increased investment in research and development will
provide bases for new products and improved practice management programs such as
new techniques to measure and cast our custom orthotics products.
ACQUISITIONS
- ------------
General
With continued advances in technology, the Company believes that the larger
orthotics manufacturers that employ advanced technologies will lower per unit
manufacturing costs, improve quality, accelerate turnaround time and will
continue to grow their overall share of the market. Concurrently, many of the
smaller orthotics manufacturers will find it increasingly difficult to remain
competitive and may not be able to access the capital required to purchase and
implement the required technological advances. Moreover, the Company believes
that many licensed medical practitioners in the industry would prefer to deal
with a consolidated entity that can provide a broad spectrum of branded
orthotics products. We believe that the orthopedic rehabilitation and recovery
market and foot orthotic device markets will consolidate as the smaller
manufacturers are acquired by the larger, and faster growing, manufacturers.
5
The Company expects to pursue a strategy of growth through acquisitions by
focusing on acquisitions of companies which have a core customer base similar to
ours and manufacture or sell products which are synergistic with our product
offerings. Orthotic manufacturing companies we may acquire are intended to
become hubs for further penetration into their industry niche or geographic
sales area. Generally, we will seek to streamline operations in acquired
companies to improve turnaround time and reduce expenses, resulting in economies
of scale, reduced general and administrative expenses and facilities
consolidation. We will seek to consolidate operations with our acquired product
manufacturing companies. This is intended to allow us to leverage efficiencies
and operational best practices.
The Company uses several criteria to evaluate prospective acquisitions,
including whether the business to be acquired:
o broadens the scope of the services or products we offer or the
geographic areas we serve;
o offers attractive margins;
o provides earnings accretion;
o offers the opportunity to enhance profitability by improving the
efficiency of our operations;
o offers consistent management with our existing businesses;
o complements our portfolio of existing businesses by increasing our
ability to manage our customers needs; and
o has a strong management team that is interested in continuing in their
roles with us.
Recent Acquisitions
On May 6, 2002, the Company acquired the net assets of Benefoot, Inc., and
Benefoot Professional Products, Inc. Benefoot, Inc., designs, manufactures and
distributes foot and gait-related biomechanical products, including custom-made
prescription orthotic devices, custom-made Birkenstock(R) sandals and
off-the-shelf orthotic devices to healthcare professionals. Benefoot
Professional Products markets and distributes footwear products to podiatrists'
patients. The purchase price was $6.1 million of which $3.8 million was paid in
cash, $1.8 million was paid through the issuance of promissory notes and $.5
million was paid by issuing to the sellers 61,805 shares of the Company's common
stock. The Company also assumed certain liabilities including approximately $.3
million of long term indebtedness. The Company also agreed to pay Benefoot up to
an additional $1.0 million upon satisfaction of certain performance targets on
or prior to May 6, 2004.
On January 13, 2003, the Company acquired all the capital stock of Bi-Op
Laboratories, Inc. which is engaged in the development, manufacture and sale of
footwear products and foot orthotic devices, for $2.45 million CDN, of which
$1.85 million CDN was paid in cash, and $.6 million CDN was paid by issuing to
the sellers 107,611 shares of the Company's common stock. $.25 million CDN of
the cash portion of the consideration was deposited in escrow until final
determination of the closing date balance sheet of Bi-Op.
PRODUCTS
- --------
The Company manufactures, markets, sells, and distributes two principal
categories of products: (i) custom orthotic devices ordered by licensed medical
practitioners and (ii) pre-fabricated orthopedic rehabilitation and recovery
devices and related devices sold to a patient by licensed medical practitioners.
These products are designed to provide relief from symptoms and complications
arising from (i) ankle, knee, pelvis, hip, and spinal pain caused by
biomechanical misalignment, (ii) diabetes, stroke, nerve damage, cerebral palsy,
multiple sclerosis and similar ailments, and (iii) post-operative recovery.
6
Custom Orthotic Devices
Orthotic foot devices, or foot orthoses, are contoured molds made from plastic,
graphite, or composite materials, depending upon the requirements of the
patient, which are placed in the patient's shoe to correct or mitigate
abnormalities in gait and relieve symptoms associated with foot or postural
alignment. Orthotic devices help provide more normal function by maintaining the
angular anatomical relationships between the patient's forefoot, rearfoot, leg
and horizontal walking surface. Accordingly, muscle is enhanced and the
efficiency and smoothness of weight stress transmission through the feet and
legs is improved. The result is a reduction of abnormal motion without total
restriction of normal motion and an increase in foot and leg stability. Foot
problems may be alleviated or eliminated, as well as leg and back fatigue caused
by improper muscle use.
Traditionally, when a licensed medical practitioner orders a custom foot
orthotic for the Company to manufacture, the licensed medical practitioner will
take a plaster cast or an imprint of the patient's foot by having the patient
stand on a piece of foam slightly larger than the patient's foot. The plaster or
foam cast is sent to our laboratory where it is used to make a plaster cast of
the patient's foot, from which we manufacture and customize the orthotic insert.
We have developed a new proprietary technology which will permit a podiatrist to
take measurements of a patient's foot at several specified locations and
transmit the measurements to us electronically. From these measurements, we will
be able to make the model of the patient's foot, from which we will manufacture
and customize the orthotic insert. We anticipate this new proprietary
technology, along with CAD/CAM technology and laser scanning, will enable us to
reduce the time required and costs associated with the production of our custom
foot orthotics.
The Company also offers a full line of custom Ankle-Foot Orthoses (AFO's)
devices, which are used to support, align, prevent, correct, substitute or
enhance function, and decrease pain or discomfort of the foot and ankle. These
products are often used for the more difficult and challenging foot and ankle
involvements.
The Company's custom orthotic product offerings include:
o Sporthotics(R), designed for the specific needs of runners and other
sport-specific athletes, including football, basketball and tennis
players;
o Healthflex(R), designed for patients that participate in aerobic
exercise, high-power walking, or step classes;
o Design-Line(R), a functional orthotic designed to fit into dress shoes,
such as loafers and high fashion shoes, which cannot accommodate a
full-size orthotic; and;
o Slimthotics(R), a device for use in women's high-heeled shoes, narrow
flats, ballet slippers, tap shoes, and women's ballroom dancing shoes.
Distributed Products
The Company distributes prefabricated orthotic devices and related orthotic
supplies and materials.
This line of prefabricated foot orthotic products is Langer XP(R), which
provides patients a low cost alternative to a custom orthotic. The products
provide additional cushioning in a patient's footwear. We provide these products
to a podiatrist or other licensed medical practitioner based upon several
criteria, including shoe size, and the licensed medical practitioner sells the
product to a patient based upon the patient's needs.
In 2000, the Company launched our prefabricated foot orthoses, called
Contours(TM), which require no special casting by the licensed medical
practitioner. This off-the-shelf product line, sold to licensed medical
practitioners through the Company and its distributors, has been expanded to
include dress (low profile), sport and standard models and provides a lower cost
option when pricing is an issue for the patient.
7
The Company also provides orthopedic devices that are used in the treatment of
ailments of the lower leg. These include products which support or control the
ankle region (ankle foot orthoses). In addition, we market products that address
the diabetic market, including insoles, and a selection of footwear (shoes,
socks, and other related products) which offers protection for patients with
diabetes. We believe these ancillary product lines will help us achieve our goal
of being able to provide a variety of orthopedic needs for our core podiatry
customer.
In many of our orthotic products, we use PPT(R), a medical grade soft tissue
cushioning material with a high density, open-celled urethane foam structure.
The essential function of PPT(R), which independent tests show to have improved
properties over competitive materials, is to provide protection against forces
of pressure, shock and shear. We believe that PPT's(R) characteristics make it a
superior product in its field. PPT(R) has a superior "memory" that enables it to
return to its original shape faster and more accurately than other materials
used for similar purposes. PPT(R) is also odorless and non-sensitizing to the
skin and has a porosity that helps the skin to remain dry, cool and comfortable.
These factors are especially important in sports medicine applications.
We have developed and sell a variety of products fabricated from PPT(R),
including molded insoles, components for orthotic devices, laminated sheets, and
diabetic products. Some manufacturing operations associated with these products
are performed by outside vendors.
Besides podiatric use, we believe PPT(R) is suitable for other orthopedic and
medical-related uses such as liners for braces and prosthetics, as shock
absorbers and generally in devices used in sports and physical therapy. We
expect to expand our products to include shock absorbing PPTGel(TM) products to
be used as shoe inserts and brace liners.
CUSTOMERS
- ---------
The majority of the Company's sales are within the United States to podiatrists,
orthopedic surgeons, orthotists, physical therapists, and other health care
professionals. However, we also sell our products in the United Kingdom, Canada,
and 30 other countries. We intend to expand our product offerings into new
territories.
The Company markets our custom orthotic products primarily to podiatrists who
order the custom orthotic devices for their patients. However, we will seek to
broaden our referral channels by increased penetration of orthopedic surgeons,
physical therapists, orthotists, chiropractors, athletic trainers, and other
podiatrists currently working in the United States. We also anticipate that we
will seek to increase our referral channels outside the United States.
The Company sells our distributed products primarily to wholesale distributors
and licensed medical practitioners for sale to patients. For both our custom
orthotics and our distributed products, licensed medical practitioners usually
include the cost of the orthotic products in the fee charged to the patient.
MARKETING AND DISTRIBUTION
- --------------------------
The Company believes that we have built strong name recognition and an excellent
reputation in the orthotics industry. We are seeking to become a more
comprehensive source of orthopedic supplies for health care professionals who
treat the lower extremities.
The Company utilizes a network of regional sales representatives to target
multi-practitioner and individual facilities. In addition, we use trade shows,
advertising, direct mail, educational sponsorships, public relations and
customer visits to market and distribute our products. We emphasize customer
service by maintaining a staff of customer service representatives.
The Company provides education and training for licensed medical practitioners
who treat biomechanical problems of the lower extremity through seminars and
in-service programs. We offer licensed medical practitioners a comprehensive
program in biomechanics, gait analysis and the cost-effectiveness of orthotic
therapy.
8
The Company promotes awareness of orthotics through marketing and operational
initiatives. We maintain a volume incentive program and offer practice building
assistance to help licensed medical practitioners expand the orthotic components
portion of their practices. We believe these medical practitioner assistance
programs strengthen our relationships with our existing customer base.
MANUFACTURING AND RAW MATERIALS
- -------------------------------
The Company manufactures our custom orthotics and warehouses our distributed
products internally at our production facilities located in Deer Park, New York;
Brea, California; Montreal, Canada; and Stoke-on-Trent, England. We obtain most
of our fabrication materials other than PPT(R) from a variety of sources. We
believe that we maintain good relationships with these suppliers. However, if
necessary, we could readily obtain alternate suppliers at a competitive price.
We are aware of multiple suppliers for these materials and would not anticipate
a significant impact if we were to lose any suppliers, and we have not
experienced any significant shortages other than occasional backorders. To date,
we have found that the components, supplies and raw materials that are necessary
for the manufacture, production and delivery of our products have been available
in the quantities that are required. However, the failure of our suppliers to
deliver components, supplies, and raw materials in sufficient quantities and in
a timely manner, and the inability to find replacement suppliers, could
adversely affect our business and results of operations.
COMPETITION
- -----------
The market for orthotic products is highly competitive and we compete with a
variety of companies ranging from small businesses to large corporations. The
Company believes the foot orthotics market is highly fragmented and regional
(and in many instances local) in nature. Although a few licensed medical
practitioners produce foot orthotics in-house, the custom orthotic market is
serviced primarily by third-party laboratories, such as the Company. Included
among these laboratories that sell nationally in the United States are Bergmann
Orthotic Laboratory, Foot Levelers, Inc., Footmaxx Holdings Inc., KLM Orthotic
Laboratories, Allied OSI Labs, ProLab Orthotics, and PAL Health Systems. We
estimate that, including Langer, these firms comprise approximately 35% of the
$200 million custom foot orthotics market in the United States.
The market for soft tissue products such as PPT(R) is highly competitive and
includes the following brand name products: Spenco, Sorbothane, and Poron.
In both the custom and distribution products markets, the principal competitive
factors are efficiencies of scale, quality of engineering and design, brand
recognition, reputation in the industry, production capability and capacity, and
price. In the custom orthotic market, ability to meet delivery schedules is
another principal competitive factor. We believe that we provide superior design
and production expertise.
MEDICAL CONSULTANTS
- -------------------
The Company has relationships with three medical specialists who provide
professional consultative services to the Company in their areas of
specialization. The consultants test and evaluate the Company's products, act as
speakers for the Company at symposiums and professional meetings, generally
participate in the development of the Company's products and services and
disseminate information about them. The Company also relies on practitioners in
various parts of the country to act as field evaluators of the Company's
products.
9
EMPLOYEES
- ---------
As of January 1, 2003, the Company had 220 employees, of which 117 were located
in Deer Park, New York, 37 were located in Brea, California, 31 were located in
Montreal, Canada and 35 were located in Stoke-on-Trent, England. None of our
employees are represented by unions or covered by any collective bargaining
agreements. The Company has not experienced any work stoppages or
employee-related slowdowns and believes that our relationship with our employees
is satisfactory.
PATENTS AND TRADEMARKS
- ----------------------
The Company holds a variety of patents, trademarks, and copyrights in several
countries, including the United States. We have exclusive licenses to three
types of orthotic devices which are patented in the United States and several
foreign countries. We believe that none of our active patents, trademarks, or
licenses are essential to the successful operation of our business as a whole.
However, one or more of the patents, trademarks, or licenses may be material in
relation to individual products or product lines. Loss of patent protection
could have an adverse effect on our business by permitting competitors to
utilize techniques developed by us.
GOVERNMENT REGULATION
- ---------------------
The jurisdictions in which we seek to market our products may regulate and
supervise our products and operations. In some circumstances, we may be required
to obtain regulatory approvals and otherwise comply with regulations regarding
safety, quality and efficacy standards. These regulations vary from country to
country, and the regulatory review can be lengthy, expensive and uncertain. In
the United States, we are subject to federal and state governmental regulation
and supervision, including anti-kickback statutes, self-referral laws, and
fee-splitting laws.
SEASONALITY
- -----------
Revenue derived from the Company's sales of orthotic devices, a substantial
portion of the Company's operations, has in North America historically been
significantly higher in the warmer months of the year, while sales of orthotic
devices by the Company's United Kingdom subsidiary has historically not
evidenced any seasonality.
10
ITEM 2. PROPERTIES
- ------------------
We have manufacturing, warehouse, and office space at the following locations:
ANNUAL OWNED/ APPROXIMATE
LOCATION RENT LEASED SIZE
- --------------------------- ------------ ----------- -------------------
Deer Park, NY $ 310,000 Leased(1) 44,500 sq. ft.
Deer Park, NY $ 24,000 Leased(2) 3,500 sq. ft.
Brea, CA $ 99,000 Leased(3) 9,300 sq. ft.
Stoke-on-Trent, England $ 42,000(4) Leased 15,000 sq. ft.
Montreal, Canada - Owned 7,800 sq. ft
(1) Principal executive office location. Expires at the end of July, 2005.
We have the option to extend the lease for an additional four (4)
years.
(2) Expires on July 31, 2004.
(3) Expires on December 31, 2004.
(4) Based upon an exchange rate of $1.6044 dollars per British pound,
expires on June 30, 2004
The Company believes our manufacturing, warehouse and office facilities are
suitable and adequate and afford sufficient capacity for our current and
reasonably foreseeable future needs. The Company believes it has adequate
insurance coverage for our properties and their contents.
ITEM 3. LEGAL PROCEEDINGS
- -------------------------
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- ------------------------------------------------------------
None.
11
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
- -----------------------------------------------------------------------------
PRICE RANGE OF COMMON STOCK
- ---------------------------
The Company's common stock, par value $.02 per share ("Common Stock"), is traded
on the over-the-counter market with quotations reported on the National
Association of Securities Dealers Automated Quotation System (NASDAQ) under the
symbol GAIT. The following table sets forth the high and low closing bid prices
for the Common Stock for the year ended December 31, 2002 and the ten months
ended December 31, 2001. The NASDAQ quotations represent prices between dealers,
do not include retail markups, markdowns or commissions, and may not represent
actual transactions.
YEAR ENDED DECEMBER 31, 2002 HIGH LOW
------------------------------------------- ---------- ----------
Three months ended March 31, 2002 $ 8.30 $ 7.11
Three months ended June 30, 2002 $ 8.25 $ 5.90
Three months ended September 30, 2002 $ 6.43 $ 4.50
Three months ended December 31, 2002 $ 5.25 $ 3.51
TEN MONTHS ENDED DECEMBER 31, 2001 HIGH LOW
------------------------------------------- ---------- ----------
One month ended March 31, 2001 $ 5.22 $ 4.00
Three months ended June 30, 2001 $ 5.25 $ 3.10
Three months ended September 30, 2001 $ 5.80 $ 3.66
Three months ended December 31, 2001 $11.85 $ 4.80
The closing price on March 25, 2003 was $3.10. On March 25, 2003, there were
approximately 249 holders of record of the Common Stock. However, this figure is
exclusive of all owners whose stock is held beneficially or in "street" name.
Based on information supplied by various securities dealers, the Company
believes that there are in excess of 249 shareholders in total, including
holders of record and beneficial owners of shares held in "street" name.
DIVIDEND HISTORY AND POLICY
- ---------------------------
The Company did not pay cash dividends on its Common Stock and anticipates that,
for the foreseeable future, it will follow a policy of retaining earnings to
finance the expansion and development of its business. In any event, future
dividend policy will depend upon the Company's earnings, financial condition,
working capital requirements and other factors.
EQUITY COMPENSATION PLANS
- -------------------------
The following table sets forth certain information regarding our equity plans
as at December 31, 2002.
- ----------------------------------------------------------------------------------------------------------------------
(a) (b) (c)
- ----------------------------------------------------------------------------------------------------------------------
Number of securities
Number of securities remaining available for
to be issued upon Weighted average exercise future issuance under equity
exercise of price of outstanding compensation plans
outstanding options, options, warrants and (excluding securities
Plan Category warrants and rights rights reflected in column (a))
- ----------------------------------------------------------------------------------------------------------------------
Equity compensation plans
approved by security holders 609,000 $2.92 1,145,213
- ----------------------------------------------------------------------------------------------------------------------
Equity compensation plans
not approved by security
holders 0 0 0
- ----------------------------------------------------------------------------------------------------------------------
Total 609,000 $2.92 1,145,213
- ----------------------------------------------------------------------------------------------------------------------
12
RECENT SALES OF UNREGISTERED SECURITIES
- ---------------------------------------
Described below is information regarding securities the Company issued in the
year ended December 31, 2002 which were not registered under the Securities Act
of 1933.
On May 6, 2002 the Company completed the acquisition of Benefoot. In connection
with the acquisition, the Company issued 64,895 shares of the Company's common
stock.
On January 13, 2003, the Company completed the acquisition of Bi-Op. In
connection with the acquisition, the Company issued 107,611 shares of the
Company's common stock.
The Company issued 787 shares of the Company's common stock to one of its
medical directors as compensation for services.
The above sales were private transactions not involving a public offering and
were exempt from the registration provisions of the Securities Act pursuant to
Section 4(2) thereof. No underwriter was engaged in connection with the
foregoing sales of securities. The Company has reason to believe that: (i) all
of the foregoing purchasers were familiar with or had access to information
concerning the Company's operations and financial condition, (ii) all of those
individuals purchasing securities represented that they acquired the shares for
investment and not with a view to the distribution thereof, and (iii) the
foregoing purchasers are accredited investors within the meaning of Regulation D
promulgated under the Securities Act.
13
ITEM 6. SELECTED FINANCIAL DATA
- --------------------------------
Ten months Year ended
Year ended ended -----------------------------------------
(in thousands, except per share data) Dec. 31, Dec. 31, Feb. 28, Feb. 29, Feb. 28,
2002 2001 2001 2000 1999
------------- ----------- ----------- ----------- -----------
$ $ $ $ $
Consolidated Statement of Operations
Net sales 18,677 10,936 12,072 11,572 10,734
Change in control and restructuring expenses - - (1,008) - -
Operating profit (loss) (353) 139 (1,504) (356) 105
Income (loss) before income taxes (998) 73 (1,502) (337) 329
Net income (loss) (1,106) 70 (1,506) (335) 304
Net income (loss) per common share:
Basic (.26) .02 (.58) (.13) .12
Diluted (.26) .02 (.58) (.13) .12
Weighted average number of common shares:
Basic 4,246 3,860 2,583 2,571 2,584
Diluted 4,246 4,307 2,583 2,571 2,607
Dec. 31, Dec. 31, Feb. 28, Feb. 29, Feb. 28,
2002 2001 2001 2000 1999
------------- ----------- ----------- ------------ -----------
$ $ $ $ $
Consolidated Balance Sheets:
Working capital 10,569 16,655 757 1,715 2,423
Total assets 23,810 20,700 4,554 4,738 5,125
Long-term liabilities
(excluding current maturities) 15,937 14,719 126 277 305
Stockholders' equity 3,112 3,866 1,599 2,536 2,934
14
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
- -------------------------------------------------------------------------------
OF OPERATIONS
-------------
The following discussion and analysis should be read in conjunction with the
financial statements and notes thereto of the Company which are included in Item
8.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
- ------------------------------------------
The Company's accounting policies are more fully described in Note 1 of Notes to
Consolidated Financial Statements. The preparation of financial statements in
conformity with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Future events and their
effects cannot be determined with absolute certainty. Therefore, the
determination of estimates requires the exercise of judgment. Actual results may
differ from these estimates under different assumptions or conditions.
Management believes the most significant accounting estimates inherent in the
preparation of the Company's consolidated financial statements include estimates
associated with its determination of liabilities related to warranty activity
and estimates associated with the Company's reserves with respect to
collectibility of accounts receivable, allowances for sales returns, inventory
valuations, and valuation allowance for deferred tax assets. Various assumptions
and other factors underlie the determination of these significant estimates. The
process of determining significant estimates is fact specific and takes into
account factors such as historical experience, current and expected economic
conditions, and product mix. The Company constantly re-evaluates these
significant factors and makes adjustments where facts and circumstances dictate.
Historically, actual results have not significantly deviated from those
determined using the estimates described above.
The warranty reserve at December 31, 2001 was $40,342. During the year ended
December 31, 2002, the Company acquired an additional reserve of $80,000
relating to the Benefoot acquisition and charged $50,342 against the reserve for
costs incurred to complete warranty repairs. The warranty reserve at December
31, 2002 was $70,000.
The allowance for doubtful accounts at December 31, 2001 was $43,269. During the
year ended December 31, 2002 the Company added $88,348 to the allowance based
upon increased net sales and it's review of the accounts receivable aging. The
Company wrote off $6,682 in uncollectible accounts. The allowance for doubtful
accounts at December 31, 2002 was $124,935.
The sales returns and allowances at December 31, 2001 was $20,944. During the
year ended December 31, 2002 the Company added $7,056 in current expense charges
to the allowance based upon the increased net sales and it's review of sales
return and allowance trends during the year. The sales returns and allowance at
December 31, 2002 was $28,000.
The inventory reserve for obsolete inventory at December 31, 2001 was $213,906.
During the year ended December 31, 2002 the Company added $14,017 of additional
reserves and wrote off $7,518 in obsolete inventory which was disposed of during
the year. The Company reviewed its inventory levels and aging and determined
that it did not need to provide additions to the reserve. The inventory reserve
for obsolete inventory at December 31, 2002 was $220,405.
15
The valuation allowance relating to deferred tax assets was $1,570,761 at
December 31, 2001 which represented a full allowance against all deferred tax
assets. During the year ended December 31, 2002, the deferred tax asset and
related valuation allowance increased by $837,480 to $2,408,241 at December 31,
2002. The Company believes a full valuation allowance is required because it is
more likely than not that these deferred tax assets will not be recognized.
RESULTS OF OPERATIONS:
- ----------------------
The following table presents the results for the year ended December 31, 2002,
the comparable unaudited pro forma results for the year ended December 31, 2001
and the comparable results for the year ended February 28, 2001. For comparative
purposes the unaudited pro forma results of operations for the twelve months
ended December 31, 2001 have been derived from the previously reported results
for the ten months ended December 31, 2001 plus the results for the two months
ended February 28, 2001, and are unaudited.
Year ended
----------------------------------------------------------
December 31, December 31, February 28,
2002 2001 2001
-------------- ------------- --------------
(unaudited)
Net sales $ 18,676,503 $ 12,782,366 $ 12,072,004
Cost of sales 11,962,104 8,503,020 8,292,850
-------------- ------------- --------------
Gross profit 6,714,399 4,279,346 3,779,154
Selling expenses 3,151,205 1,623,259 2,011,390
Research and development expenses 164,872 182,497 252,345
General and administrative expenses 3,751,295 2,768,134 2,010,905
Change in control expenses - 795,667 1,008,081
-------------- ------------- --------------
Income (loss) from operations (352,973) (1,090,211) (1,503,567)
-------------- ------------- --------------
Other income (expense):
Interest income 214,481 86,614 3,440
Interest expense (636,393) (112,696) (20,062)
Other (223,478) (42,367) 18,329
-------------- ------------- --------------
Other income (expense), net (645,390) (68,449) 1,707
-------------- ------------- --------------
Income (loss) before income taxes (998,363) (1,158,660) (1,501,860)
Provision for income taxes 107,294 3,118 4,527
-------------- ------------- --------------
Net income (loss) $ (1,105,657) $ (1,161,778) $ (1,506,387)
============== ============= ==============
Net sales for the year ended December 31, 2002 were $18,676,503 as compared to
$12,782,366 for the comparable unaudited pro forma year ended December 31, 2001
and $12,072,004 for the year end February 28, 2001. Net sales attributable to
the Benefoot acquisition approximated $4,899,000 for the year ended December 31,
2002. Net sales exclusive of net sales attributable to the Benefoot acquisition
increased approximately $995,000 primarily as a result of increased net sales of
custom orthotic products offset slightly by a decline in distributed products.
The increase in net sales for the unaudited pro forma year ended December 31,
2001 as compared to the year ended February 28, 2001 resulted from an increase
in orthotic net sales partially offset by a decrease in net sales of distributed
products.
16
Net sales of orthotic products were $14,668,572 for the year ended December 31,
2002 as compared to $11,422,835 for the comparable unaudited pro forma year
ended December 31, 2001 and $10,335,852 for the year ended February 28, 2001.
Net sales of custom orthotic products attributable to the Benefoot acquisition
approximated $2,702,000 for the year ended December 31, 2002. Net sales of
custom orthotic products exclusive of net sales attributable to the Benefoot
acquisition increased approximately $544,000 or 4.8% primarily as a result of
increased sales in the Company's base business. The increase in net sales for
the unaudited pro forma year ended December 31, 2001 as compared to the year
ended February 28, 2001 was principally due to increased unit volume resulting
from increased turnaround time and increased results form sales representatives
in both the Company's United States and United Kingdom operations.
Net sales of distributed products were $4,007,931 for the year ended December
31, 2002 as compared to $1,359,531 for the comparable unaudited pro forma year
ended December 31, 2001 and $1,736,152 for the year ended February 28, 2001. Net
sales of distributed products attributable to the Benefoot acquisition
approximated $2,197,000 for the year ended December 31, 2002. Net sales of
distributed products exclusive of net sales attributable to the Benefoot
acquisition increased approximately $451,000 as a result of increases in sales
of PPT and our distributed products. The decrease in net sales of distributed
products for the unaudited pro forma year ended December 31, 2001 as compared to
the year ended February 28, 2001 was principally due to lower sales of PPT(R) in
the United States operations.
Gross profit as a percentage of net sales was 35.9% for the year ended December
31, 2002 as compared to 33.5% for the unaudited pro forma year ended December
31, 2001 and 31.3% for the year ended February 28, 2001. Gross profit for 2002
improved primarily as a result of improvements in efficiencies in the
manufacturing process, reductions in overhead costs and increased sales. Gross
profit for the pro forma year ended December 31, 2001 improved as compared to
the year ended February 28, 2001 primarily as a result of efficiencies in
manufacturing costs which resulted in reduced overhead costs.
Selling expenses were $3,151,205 or 16.9% of net sales for the year ended
December 31, 2002 as compared to $1,623,259 or 12.7% of net sales for the
unaudited pro forma year ended December 31, 2001 and $2,011,390 or 16.7% of net
sales for the year ended February 28, 2001. Selling expenses in the 2002 year
increased over the comparable pro forma 2001 year due to the effect of the
Benefoot acquisition, increased salaries and related costs for the investments
made in improving our sales and marketing infrastructure, and increased
promotional activity. Selling expenses for the 2001 pro forma year decreased
slightly due to efficiencies and cost reductions instituted subsequent to the
change of control in February 2001.
General and administrative expenses were $3,751,295 or 20% of net sales for the
year ended December 31, 2002 as compared to $2,768,134 or 21.7% of net sales for
the unaudited pro forma year ended December 31, 2001 and $2,010,905 or 16.7% of
net sales for the year ended February 28, 2001. General and administrative
expenses increased in the year ended December 31, 2002 as compared to the pro
forma year ended December 31, 2001 as a result of increased cost of salaries as
we strengthened our infrastructure, costs attributable to the Company's
incentive plan and costs attributable to the integration of the Benefoot
acquisition. General and administrative costs as a percentage of sales decreased
to 20% as a result of the increase in sales primarily attributable to the
Benefoot acquisition. General and administrative costs for the pro forma year
ended December 31, 2001 increased primarily as a result of higher salary costs,
implementation of the Company's incentive plan, increased consulting fees and
higher bank fees due to increased credit card sales. These expenses were
necessary as the Company expanded its infrastructure in anticipation of
executing the Company's internal growth and acquisition strategy.
17
Other income (expense) was $(645,390) for the year ended December 31, 2002 as
compared to $(68,449) for the unaudited pro forma year ended December 31, 2001
and $1,707 for the year ended February 28, 2001. The increase in other expense
is attributable to interest expense and amortization of financing costs on the
4% convertible subordinated notes issued on October 31, 2001 and the 4% Notes
issued in connection with the acquisition of Benefoot on May 6, 2002 offset in
part by interest earned from overnight investment of cash. The increase in
expense for the pro forma year ended December 31, 2001 as compared to the year
ended February 28, 2001 resulted from an increase in interest expense
attributable to the 4% convertible subordinated debentures issued on October 31,
2001 offset in part by interest earned from overnight investment of cash.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
Working capital as of December 31, 2002 was $10,568,549 as compared to
$16,655,179 at December 31, 2001. Cash balances at December 31, 2002 were
$9,411,710, a decrease of $6,385,212 from December 31, 2001. The decline in
working capital and cash is attributable to the acquisition of Benefoot.
Intangible assets and goodwill acquired amounted to approximately $6,616,000.
On October 31, 2001, the Company sold $14,589,000 of its 4% convertible
subordinated notes, due August 31, 2006, in a private placement (the "Notes").
The Notes are convertible into the Company's common stock at a conversion price
of $6.00 per share and are subordinated to all existing or future senior
indebtedness of the Company. The Company received net proceeds of $13,668,067
from this offering. The costs of raising these proceeds, including placement and
legal fees, was $920,933, which is being amortized over the life of the Notes.
The amortization of these costs for the year ended December 31, 2002 and for the
ten-month period ended December 31, 2001 was $193,105 and $30,698, respectively.
Interest is payable semi-annually on the last date in June and December.
Interest expense for the year ended December 31, 2002 and the ten months ended
December 31, 2001 on these Notes was $583,560 and $97,260, respectively.
The Company issued $1,800,000 in Promissory Notes in connection with the
acquisition of Benefoot. $1,000,000 of the notes is due on May 6, 2003 and the
balance is due on May 6, 2004. Interest expense from the date of acquisition was
$47,200.
Certain of the Company's facilities and equipment are leased under
noncancellable operating leases. The following is a schedule, by fiscal year, of
future minimum rental payments required under current operating leases as of
December 31, 2002:
FISCAL YEAR ENDING DECEMBER 31: AMOUNT
------------------------------- ------
2003 $ 505,000
2004 473,000
2005 200,000
2006 and thereafter 10,000
The Company may finance acquisitions of other companies or product lines in the
future from existing cash balances, from borrowings from institutional lenders,
and/or the public or private offerings of debt or equity securities. Management
believes that its existing cash balances will be adequate to meet the Company's
cash needs during the fiscal year ending December 31, 2003.
The Company's United Kingdom subsidiary maintains a line of credit with a local
bank in the amount of 50,000 British pounds, which is guaranteed by the Company
pursuant to a standby Letter of Credit. If this credit facility, which has been
renewed through February 2004, would not be available, the Company believes it
can readily find a suitable replacement or the Company would supply the
necessary capital.
18
INFLATION
- ---------
The Company has in the past been able to increase the prices of its products or
reduce overhead costs sufficiently to offset the effects of inflation on wages,
materials and other expenses, and anticipates that it will be able to continue
to do so in the future.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
- -----------------------------------------
In June 2001, the Financial Accounting Standards Board (FASB) issued Statement
of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations."
SFAS No. 141 applies prospectively to all business combinations initiated after
June 30, 2001, and all business combinations accounted using the purchase method
for which the date of acquisition is July 1, 2001, or later. This statement
requires all business combinations to be accounted for using one method, the
purchase method. Under previously existed accounting rules, business
combinations were accounted for using one of two methods, pooling-of-interests
method or the purchase method. As of January 1, 2002 the Company adopted the
provisions of SFAS No. 141. Accordingly, the Company accounted for it's
acquisition of Benefoot under the purchase method accounting.
In June 2001, the FASB issued SFAS No. 142, "Goodwill and Other Intangible
Assets." SFAS No. 142 addresses financial accounting and reporting for acquired
goodwill and other intangible assets. Under SFAS No. 142, goodwill and some
intangible assets will no longer be amortized, but rather reviewed for
impairment on a periodic basis. As of January 1, 2002 the Company adopted the
provisions of SFAS No. 142. Therefore, goodwill and certain identifiable
intangible assets with indefinite lives have not been amortized and will be
reviewed for impairment on an annual basis.
In August 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement
Obligations." This standard requires entities to record the fair value of a
liability for an asset retirement obligation in the period in which it is
incurred. When the liability is initially recorded, the entity capitalizes a
cost by increasing the carrying amount of the related long-lived asset. Over
time the liability is accreted to its present value each period and the
capitalized cost is depreciated over the useful life of the related asset. Upon
settlement of the liability, an entity either settles the obligation for its
recorded amount or incurs a gain or loss upon settlement. The standard is
effective for fiscal years beginning after June 15, 2002. The adoption of SFAS
No. 143 is not expected to have a material impact on the Company's financial
statements.
In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets." SFAS No. 144 replaces SFAS No. 121, "Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed
Of." SFAS No. 144 requires that long-lived assets be measured at the lower of
carrying amount or fair value less cost to sell, whether reported in continuing
operations or in discontinued operations. Therefore, discontinued operations
will no longer be measured at net realizable value or include amounts for
operating losses that have not yet occurred. SFAS No. 144 also broadens the
reporting of discontinued operations to include all components of an entity with
operations that can be distinguished from the rest of the entity and that will
be eliminated from the ongoing operations of the entity in a disposal
transaction. The provisions of SFAS No. 144 are effective for financial
statements issued for fiscal years beginning after December 15, 2001. As of
January 1, 2002 the Company adopted the provisions of SFAS No. 144. The adoption
of SFAS No. 144 did not have a significant impact on the Company's financial
statements.
19
In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No.
4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections."
SFAS No. 145, among other things, rescinds SFAS No. 4, which required all gains
and losses from the extinguishment of debt to be classified as an extraordinary
item and amends SFAS No. 13 to require that certain lease modifications that
have economic effects similar to sale-leaseback transactions be accounted for in
the same manner as sale-leaseback transactions. The rescission of SFAS No. 4 is
effective for fiscal years beginning after May 15, 2002. The remainder of the
statement is generally effective for transactions occurring after May 15, 2002
with earlier application encouraged. The Company does not expect the adoption of
SFAS No. 145 to have a material impact on its consolidated financial statements.
In June 2002, the FASB issued SFAS No. 146, "Accounting for Exit or Disposal
Activities." This statement addresses the recognition, measurement and reporting
of costs that are associated with exit and disposal activities. This statement
includes the restructuring activities that are currently accounted for pursuant
to the guidance set forth in EITF 94-3, "Liability Recognition for Certain
Employee Termination Benefits and other Costs to exit an Activity (including
Certain Costs Incurred in a Restructuring)," costs related to terminating a
contract that is not a capital lease and one-time benefit arrangements received
by employees who are involuntarily terminated- nullifying the guidance under
EITF 94-3. Under SFAS No. 146 the cost associated with an exit or disposal
activity is recognized in the periods in which it is incurred rather than at the
date the company committed to the exit plan. This statement is effective for
exit or disposal activities initiated after December 31, 2002 with earlier
application encouraged. The Company does not believe that the adoption of SFAS
No. 146 will have a material effect on its consolidated financial statements.
In November 2002, the FASB issued Financial Interpretation ("FIN") 45,
"Guarantor's Accounting and Disclosure Requirements for Guarantees, Including
Indirect Guarantees of Indebtedness of Others." FIN 45 requires that the
guarantor recognize, at the inception of certain guarantees, a liability for the
fair value of the obligation undertaken in issuing such guarantee. FIN 45 also
requires additional disclosure requirements about the guarantor's obligations
and under certain guarantees that it has issued. The initial recognition and
measurement provisions of this interpretation are applicable on a prospective
basis to guarantees issued or modified after December 31, 2002. The disclosure
requirements of this interpretation are effective for financial statement
periods ending after December 15, 2002. The Company has included the required
disclosures under FIN 45 in the notes to the consolidated financial statements.
In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock Based
Compensation-Transitions and Disclosure- an amendment of FASB Statements No.
123." This amendment provides alternative methods of transition for voluntary
change to the fair value based method of accounting for stock-based employee
compensation. Additionally, prominent disclosures in both annual and interim
financial statements are required for the method of accounting for stock-based
employee compensation and the effect of the method used on reported results. The
Company will continue to account for it's stock based awards using the intrinsic
value method and has disclosed the required information under SFAS No. 148 in
the Notes to the consolidated financial statements.
In 2002, the Company adopted the provision of Emerging Issues Task Force
("EITF") Consensus No. 00-10 "Accounting for Shipping and Handling Fees and
Costs," which addresses the income statement classification for shipping and
handling fees. In accordance with EITF 00-10, net sales and cost of sales have
been increased by $407,445 and $429,852 for the ten months ended December 31,
2001 and the year ended February 28, 2001, respectively. Net sales and cost of
sales have been restated from previously issued reports. The change in
classification had no impact on the Company's consolidated results of
operations, cash flows or financial position.
20
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS
- ----------------------------------------------
Information contained or incorporated by reference in the annual report on Form
10-K, in other SEC filings by the Company, in press releases, and in
presentations by the Company or its management, contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 which can be identified by the use of forward-looking terminology such
as "believes," "expects," "plans," "intends," "estimates," "projects," "could,"
"may," "will," "should," or "anticipates" or the negative thereof, other
variations thereon or comparable terminology, or by discussions of strategy. No
assurance can be given that future results covered by the forward-looking
statements will be achieved, and other factors could also cause actual results
to vary materially from the future results covered in such forward-looking
statements. Such forward-looking statements include, but are not limited to,
those relating to the Company's financial and operating prospects, future
opportunities, the Company's acquisition strategy and ability to integrate
acquired companies and assets, outlook of customers, and reception of new
products, technologies, and pricing. In addition, such forward-looking
statements involve known and unknown risks, uncertainties, and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results expressed or implied by such
forward-looking statements. Also, the Company's business could be materially
adversely affected and the trading price of the Company's common stock could
decline if any such risks and uncertainties develop into actual events. The
Company undertakes no obligation to publicly update or revise forward-looking
statements to reflect events or circumstances after the date of this Form 10-K
or to reflect the occurrence of unanticipated events.
21
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- -------------------------------------------------------------------
In general, business enterprises can be exposed to market risks, including
fluctuation in commodity and raw materials prices, foreign currency exchange
rates, and interest rates that can adversely affect the cost and results of
operating, investing, and financing. In seeking to minimize the risks and/or
costs associated with such activities, the Company manages exposure to changes
in commodities and raw material prices, interest rates and foreign currency
exchange rates through its regular operating and financing activities. The
Company does not utilize financial instruments for trading or other speculative
purposes, nor does the Company utilize leveraged financial instruments or other
derivatives. The following discussion about our market rate risk involves
forward-looking statements. Actual results could differ materially from those
projected in the forward-looking statements.
The Company's exposure to market rate risk for changes in interest rates relates
primarily to the Company's short-term monetary investments. There is a market
rate risk for changes in interest rates earned on short-term money market
instruments. There is inherent rollover risk in the short-term money market
instruments as they mature and are renewed at current market rates. The extent
of this risk is not quantifiable or predictable because of the variability of
future interest rates and business financing requirements. However, there is no
risk of loss of principal in the short-term money market instruments, only a
risk related to a potential reduction in future interest income. Derivative
instruments are not presently used to adjust the Company's interest rate risk
profile.
The majority of the Company's business is denominated in United States dollars.
There are costs associated with the Company's operations in foreign countries,
primarily the United Kingdom and Canada, which require payments in the local
currency and payments received from customers for goods sold in these countries
are typically in the local currency. The Company partially manages its foreign
currency risk related to those payments by maintaining operating accounts in
these foreign countries and by having customers pay the Company in those same
currencies.
22
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA
LANGER, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE II
PAGE
Independent Auditors' Report 24
Consolidated Financial Statements:
Consolidated Balance Sheets 25
Consolidated Statements of Operations 26
Consolidated Statements of Stockholders' Equity 27
Consolidated Statements of Cash Flows 28
Notes to Consolidated Financial Statements 29
Consolidated Financial Statement Schedule II -
Valuation and Qualifying Accounts 46
All other schedules have been omitted because they are not applicable, not
required or the information is disclosed in the consolidated financial
statements, including the notes thereto.
23
INDEPENDENT AUDITORS' REPORT
To the Stockholders and Board of Directors of
Langer, Inc. and Subsidiaries
We have audited the accompanying consolidated balance sheets of Langer, Inc. and
subsidiaries (the "Company") as of December 31, 2002 and 2001, and the related
consolidated statements of operations, stockholders' equity and cash flows for
the year ended December 31, 2002, for the ten months ended December 31, 2001,
and for the year ended February 28, 2001. Our audits also included the financial
statement schedule listed in the foregoing index for the year ended December 31,
2002, for the ten months ended December 31, 2001, and for the year ended
February 28, 2001. These consolidated financial statements and financial
statement schedule are the responsibility of the Company's management. Our
responsibility is to express an opinion on the consolidated financial statements
based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the consolidated financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall consolidated financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December 31, 2002
and 2001, and the results of its operations and its cash flows for the year
ended December 31, 2002, for the ten months ended December 31, 2001, and for the
year ended February 28, 2001, in conformity with accounting principles generally
accepted in the United States of America. Also, in our opinion, such financial
statement schedule, when considered in relation to the basic consolidated
financial statements taken as a whole, presents fairly in all material respects
the information set forth therein.
DELOITTE & TOUCHE LLP
Jericho, New York
March 27 , 2003
24
LANGER, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31,
-----------------------------------
2002 2001
---------------- ---------------
Assets
Current assets:
Cash and cash equivalents $ 9,411,710 $ 15,796,922
Accounts receivable, net of allowance for doubtful
accounts of approximately $124,935 and $43,269 respectively 2,937,340 1,646,696
Inventories, net (Note 3) 2,353,153 1,141,151
Prepaid expenses and other 627,154 185,740
---------------- ---------------
Total current assets 15,329,357 18,770,509
Property and equipment, net (Note 4) 943,893 701,996
Identifiable intangible assets, net (Note 2) 3,313,413 --
Goodwill 3,186,386 --
Other assets (Notes 8 and 11) 1,037,105 1,227,741
---------------- ---------------
Total assets $ 23,810,154 $ 20,700,246
================ ===============
Liabilities and stockholders' equity
Current liabilities:
Current maturities of long-term debt (Note 6) $ 1,000,000 $ --
Accounts payable 1,235,598 429,531
Other current liabilities (Notes 5 and 12) 1,864,344 1,224,444
Unearned revenue (Note 1) 660,866 461,355
---------------- ---------------
Total current liabilities 4,760,808 2,115,330
Long-term debt (Note 6) 15,389,000 14,589,000
Unearned revenue (Note 1) 162,455 113,740
Accrued pension expense (Note 11) 209,539 --
Other (Note 12) 176,138 15,967
---------------- ---------------
Total liabilities 20,697,940 16,834,037
---------------- ---------------
Commitments and contingencies (Note 7) -- --
Stockholders' equity (Note 9):
Common stock, $.02 par value. Authorized 50,000,000 and
10,000,000 shares; issued 4,336,744 and
4,268,022 shares, respectively 86,735 85,361
Additional paid-in capital 12,825,237 12,258,724
Accumulated deficit (9,153,669) (8,048,012)
Accumulated other comprehensive loss (Note 11) (530,632) (314,407)
---------------- ---------------
3,227,671 3,981,666
Treasury stock at cost, 67,100 shares (115,457) (115,457)
---------------- ---------------
Total stockholders' equity 3,112,214 3,866,209
---------------- ---------------
Total liabilities and stockholders' equity $ 23,810,154 $ 20,700,246
================ ===============
See accompanying notes to consolidated financial statements.
25
LANGER, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
TEN MONTHS
YEAR ENDED ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, FEBRUARY 28,
2002 2001 2001
------------ ------------ ------------
Net sales $ 18,676,503 $ 10,936,112 $ 12,072,004
Cost of sales 11,962,104 6,934,402 8,292,850
------------ ------------ ------------
Gross profit 6,714,399 4,001,710 3,779,154
Selling expenses 3,151,205 1,294,991 2,011,390
Research and development expenses 164,872 142,192 252,345
General and administrative expenses 3,751,295 2,425,177 2,010,905
Change in control and restructuring expenses (Note 8) -- -- 1,008,081
------------ ------------ ------------
Operating income (loss) (352,973) 139,350 (1,503,567)
------------ ------------ ------------
Other income (expense):
Interest income 214,481 86,635 3,440
Interest expense (636,393) (108,148) (20,062)
Other (223,478) (44,440) 18,329
------------ ------------ ------------
Other (expense) income, net (645,390) (65,953) 1,707
------------ ------------ ------------
Income (loss) before income taxes (998,363) 73,397 (1,501,860)
Provision for income taxes (Note 12) 107,294 3,118 4,527
------------ ------------ ------------
Net income (loss) $ (1,105,657) $ 70,279 $ (1,506,387)
============ ============ ============
Weighted average number of common shares used in
computation of net income (loss) per share:
Basic 4,245,711 3,860,167 2,582,615
============ ============ ============
Diluted 4,245,711 4,306,536 2,582,615
============ ============ ============
Net income (loss) per common share:
Basic $ (.26) $ .02 $ (.58)
============ ============ ============
Diluted $ (.26) $ .02 $ (.58)
============ ============ ============
See accompanying notes to consolidated financial statements
26
LANGER, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Common Stock
---------------------
Additional
Treasury paid-in Accumulated
Shares Amount stock capital deficit
--------- --------- ----------- ------------ ------------
Balance at March 1, 2000: 2,640,281 $ 52,806 $ (136,193) $ 6,325,880 $ (3,405,904)
Net loss (1,506,387)
Foreign currency adjustment
Minimum pension liability
adjustment
Total comprehensive (loss)
Issuance of stock 147,541 2,951 222,049
Issuance of shares from
treasury 100,949
Non-cash dividend 3,206,000 (3,206,000)
Treasury stock acquired (80,213)
Issuance of stock options for
consulting services 245,000
Exercise of stock options 61,200 1,224 87,626
--------- --------- ----------- ------------ ------------
Balance at February 28, 2001: 2,849,022 56,981 (115,457) 10,086,555 (8,118,291)
Net income for ten months
ended December 31, 2001 70,279
Foreign currency
adjustment
Minimum pension
liability adjustment
Total comprehensive income
Issuance of stock 1,400,000 28,000 2,107,000
Exercise of stock options 19,000 380 30,183
Issuance of stock options for
consulting services 8,243
Compensation expense to
accelerate stock options 26,743
--------- --------- ----------- ------------ ------------
Balance at December 31, 2001 4,268,022 85,361 (115,457) 12,258,724 (8,048,012)
Net loss (1,105,657)
Foreign currency adjustment
Minimum pension liability
adjustment
Total comprehensive (loss)
Issuance of stock to
purchase business 64,895 1,298 528,214
Issuance of stock and
exercise of stock options 3,827 76 11,729
Issuance of stock
options for consulting
services 6,513
Compensation expense to
accelerate stock options 20,057
--------- --------- ----------- ------------ ------------
Balance at December 31, 2002 4,336,744 $ 86,735 $ (115,457) $ 12,825,237 $ (9,153,669)
========= ========= =========== ============ ============
Accumulated Other
Comprehensive Income
(Loss)
------------------------------
Foreign Minimum Total
currency pension Comprehensive stockholders'
translation liability income equity
----------- ----------- ------------ --------------
Balance at March 1, 2000: $ (47,507) $ (252,759) - $ 2,536,323
Net loss $ (1,506,387)
Foreign currency adjustment (5,227) (5,227)
Minimum pension
liability adjustment (4,964) (4,964)
------------
Total comprehensive (loss) $ (1,516,578) (1,516,578)
============
Issuance of stock 225,000
Issuance of shares from
treasury 100,949
Non-cash dividend -
Treasury stock acquired (80,213)
Issuance of stock options for
consulting services 245,000
Exercise of stock options 88,850
----------- ----------- ------------ --------------
Balance at February 28, 2001: (52,734) (257,723) 1,599,331
Net income for ten months
ended December 31, 2001 $ 70,279
Foreign currency adjustment (53) (53)
Minimum pension
liability adjustment (3,897) (3,897)
------------
Total comprehensive income $ 66,329 66,329
============
Issuance of stock 2,135,000
Exercise of stock options 30,563
Issuance of stock options for
consulting services 8,243
Compensation expense to
accelerate stock options 26,743
----------- ----------- ------------ --------------
Balance at December 31, 2001 (52,787) (261,620) 3,866,209
Net loss $ (1,105,657)
Foreign currency adjustment 26,570 26,570
Minimum pension liability
adjustment (242,795) (242,795)
------------
Total comprehensive (loss) $ (1,321,882) (1,321,882)
============
Issuance of stock to
purchase business 529,512
Issuance of stock and exercise
of stock options 11,805
Issuance of stock options for
consulting services 6,513
Compensation expense to
accelerate stock options 20,057
----------- ----------- --------------
Balance at December 31, 2002 $ (26,217) $ (504,415) $ 3,112,214
=========== =========== ==============
See accompanying notes to consolidated financial statements.
27
LANGER, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
TEN MONTHS
YEAR ENDED ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, FEBRUARY 28,
2002 2001 2001
---------------- ---------------- ----------------
Cash Flows From Operating Activities:
Net income (loss) $ (1,105,657) $ 70,279 $ (1,506,387)
Adjustments to reconcile net income (loss) to net cash
(used in) provided by operating activities:
Depreciation and amortization 648,215 254,921 301,902
Compensation expense for options acceleration 20,057 26,743 --
Provision for doubtful accounts receivable 88,348 15,015 19,000
Deferred income taxes 79,606 7,181 976
Issuance of stock and stock options for consulting services 11,755 8,243 245,000
Changes in operating assets and liabilities:
Accounts receivable (533,849) (116,976) (262,412)
Inventories (519,701) (166,021) 206,813
Prepaid expenses and other assets (389,302) (932,588) 26,106
Accounts payable and other current liabilities 356,231 (168,549) 367,861
Unearned revenue and other liabilities (10,175) 28,416 (59,445)
---------------- ---------------- ----------------
Net cash (used in) operating activities (1,354,472) (973,336) (660,586)
---------------- ---------------- ----------------
Cash Flows From Investing Activities:
Purchase of fixed assets (333,697) (271,693) (49,381)
Purchase of business, net of cash acquired (4,703,606) -- (145,138)
---------------- ---------------- ----------------
Net cash (used in) investing activities (5,037,303) (271,693) (194,519)
---------------- ---------------- ----------------
Cash Flows From Financing Activities:
Proceeds from the exercise of stock options 6,563 30,563 88,850
Issuance of common stock for purchase of business -- -- 65,139
Proceeds from issuance of debt -- 14,589,000 500,000
Payments on debt -- (581,458) (28,750)
Issuance of shares from option exercise -- 2,135,000 --
Treasury stock (acquired) issued -- -- (80,213)
Issuance of common stock -- -- 260,810
---------------- ---------------- ----------------
Net cash provided by financing activities 6,563 16,173,105 805,836
---------------- ---------------- ----------------
Net (decrease) increase in cash and cash equivalents (6,385,212) 14,928,076 (49,269)
Cash and cash equivalents at beginning of period 15,796,922 868,846 918,115
---------------- ---------------- ----------------
Cash and cash equivalents at end of period $ 9,411,710 $ 15,796,922 $ 868,846
================ ================ ================
Supplemental Disclosures of Cash Flow Information
Cash paid during the period for:
Interest $ 636,393 $ 110,548 $ 17,663
================ ================ ================
Income taxes $ -- $ -- $ 2,348
================ ================ ================
See accompanying notes to consolidated financial statements.
28
LANGER, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(A) CHANGE IN NAME AND FISCAL YEAR END AND STATE OF INCORPORATION
At the Company's July 17, 2001 annual meeting, the shareholders
approved changing the name of the Company from The Langer Biomechanics
Group, Inc. to Langer, Inc. Additionally, the stockholders approved
changing the fiscal year end from February 28 to December 31 of each
year. At the Company's June 27, 2002 annual meeting, the shareholders
approved changing the state of incorporation from New York to
Delaware.
(B) DESCRIPTION OF THE BUSINESS
The Company is a leading orthotics products company specializing in
the designing, manufacturing, distributing and marketing of high
quality foot and gait-related biomechanical products. The Company's
diversified range of products is comprised of (i) custom orthotic
devices ordered by licensed medical practitioners and (ii)
distribution of pre-fabricated orthopedic rehabilitation and recovery
devices and related devices sold to a patient by licensed medical
practitioners.
(C) PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the
accounts of Langer, Inc. and its subsidiaries (the "Company"). All
significant intercompany transactions and balances have been
eliminated in consolidation.
(D) REVENUE RECOGNITION
Revenue from the sale of the Company's products is recognized at
shipment. Revenues derived from extended warranty contracts relating
to sales of orthotics are recorded as deferred revenue and recognized
over the lives of the contracts (24 months) on a straight-line basis.
(E) CASH EQUIVALENTS
For purposes of the statement of cash flows, the Company considers all
short-term, highly liquid investments purchased with a maturity of
three months or less to be cash equivalents (money market funds and
short-term commercial paper).
(F) INVENTORIES
Inventories are stated at the lower of cost or market. Cost is
determined using the first-in, first-out (FIFO) method.
29
(G) PROPERTY AND EQUIPMENT
Property and equipment is stated at cost less accumulated depreciation
and amortization. Depreciation and amortization are calculated using
the straight-line method. The lives on which depreciation and
amortization are computed are as follows:
Office furniture and equipment 3-10 years
Computer equipment and software 3-5 years
Machinery and equipment 5-10 years
Leasehold improvements lesser of 5 years or life of lease
Automobiles 3-5 years
The Company reviews long-lived assets and certain identifiable
intangibles whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. If the sum of
expected future cash flows (undiscounted and without interest charges)
is less than the carrying value of the asset, an impairment loss is
recognized. Otherwise, an impairment loss is not recognized. If an
impairment loss is required, the amount of such loss is equal to the
excess of the carrying value of the impaired asset over its fair
value.
(H) INCOME TAXES
The Company accounts for income taxes in accordance with SFAS No. 109.
Under this method, deferred tax assets and liabilities are determined
based on differences between financial reporting and tax bases of
assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to
reverse.
(I) NET INCOME (LOSS) PER SHARE
Basic earnings per share are based on the weighted average number of
shares of common stock outstanding during the period. Diluted earnings
per share are based on the weighted average number of shares of common
stock and common stock equivalents (options, warrants and convertible
subordinated notes) outstanding during the period, except where the
effect would be antidilutive, computed in accordance with the treasury
stock method.
(J) FOREIGN CURRENCY TRANSLATION
Assets and liabilities of the foreign subsidiary have been translated
at year-end exchange rates, while revenues and expenses have been
translated at average exchange rates in effect during the year.
Resulting cumulative translation adjustments have been recorded as a
separate component of accumulated other comprehensive loss in
stockholders' equity.
(K) RECLASSIFICATIONS
Certain amounts in the prior years' financial statements have been
reclassified to conform to the current year's presentation.
(L) USE OF ESTIMATES
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
30
(M) FAIR VALUE OF FINANCIAL INSTRUMENTS
At December 31, 2002 and 2001 the carrying amount of the Company's
financial instruments, including cash and cash equivalents, accounts
receivable, accounts payable and accrued liabilities, approximated
fair value because of their short-term maturity. The carrying value of
long-term debt at December 31, 2002 and 2001 also approximated fair
value based on borrowing rates currently available to the Company for
debt with similar terms.
(N) INTERNAL USE SOFTWARE
In accordance with Statement of Position 98-1, "Accounting for the
Costs of Computer Software Developed or Obtained for Internal Use",
the Company capitalizes internal-use software costs upon the
completion of the preliminary project stage and ceases capitalization
when the software project is substantially complete and ready for its
intended use. Capitalized costs are amortized on a straight-line basis
over the estimated useful life of the software, but in no event more
than four years.
(O) DERIVATIVE FINANCIAL INSTRUMENTS
As of March 1, 2001, the Company adopted Statement of Financial
Accounting Standards No. 133 "Accounting for Derivative Instruments
and Hedging Activities" ("SFAS No. 133"), as amended. As a result of
adopting SFAS No. 133, the Company recognizes all derivative financial
instruments in the consolidated financial statements at fair value
regardless of the purpose or intent for holding the instrument.
Changes in the fair value of derivative financial instruments are
either recognized periodically in income or in stockholders' equity as
a component of other comprehensive income depending on whether the
derivative financial instrument qualifies for hedge accounting or, if
so, whether it qualifies as a fair value or cash flow hedge.
Generally, the changes in the fair value of derivatives accounted for
as fair value hedges are recorded in income along with the portions of
the changes in the fair value of the hedged item that relate to the
hedged risks. Changes in the fair value of derivatives accounted for
as cash flow hedges, to the extent they are effective as hedges, are
recorded in other comprehensive income net of deferred taxes. Changes
in fair values of derivatives not qualifying as hedges are reported in
income. To date, the Company has not entered into any derivative
financial instruments. The adoption of SFAS No. 133 did not have a
material impact on the results reported in the consolidated financial
statements.
31
(P) STOCK OPTIONS
At December 31, 2002, the Company has two stock-based employee
compensation plans, which are described more fully in Note 9. The
Company accounts for those plans under the recognition and measurement
principles of APB Opinion No. 25, Accounting for Stock Issued to
Employees, and related Interpretations. No stock-based employee
compensation cost is reflected in net income, as all options granted
under those plans had an exercise price equal to market value of the
underlying common stock on the date of grant. The following table
illustrates the effect on net income and earnings per share if the
company had applied the fair value recognition provisions of FASB
Statement No. 123, Accounting for Stock-Based Compensation, to
stock-based employee compensation.
Periods ended
------------------------------------------------------------
December 31, December 31, February 28,
2002 2001 2001
-------------- -------------- ---------------
Net income (loss) - as reported $ (1,105,657) $ 70,279 $ (1,506,387)
Deduct: Total stock-based employee
compensation expense determined
under fair value basis method for
all awards, net of tax (78,695) (67,263) (327,545)
-------------- -------------- ---------------
Pro forma net income (loss) $ (1,184,352) $ 3,016 $ (1,833,932)
============== ============== ===============
Earnings Per Share:
Basic - as reported $ (.26) $ .02 $ (.58)
============== ============== ===============
Basic - pro forma $ (.28) $ .00 $ (.71)
============== ============== ===============
Diluted- as reported $ (.26) $ .02 $ (.58)
============== ============== ===============
Diluted- pro forma $ (.28) $ .00 $ (.71)
============== ============== ===============
(Q) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In June 2001, the Financial Accounting Standards Board (FASB) issued
SFAS No. 141, "Business Combinations." SFAS No. 141 applies
prospectively to all business combinations initiated after June 30,
2001, and all business combinations accounted using the purchase
method for which the date of acquisition is July 1, 2001, or later.
This statement requires all business combinations to be accounted for
using one method, the purchase method. Under previously existed
accounting rules, business combinations were accounted for using one
of two methods, pooling-of-interests method or the purchase method. As
of January 1, 2002 the Company adopted the provisions of SFAS No. 141.
Accordingly, the Company accounted for it's acquisition of Benefoot
under the purchase method of accounting.
32
In June 2001, the FASB issued SFAS No. 142, "Goodwill and Other
Intangible Assets." SFAS No. 142 addresses financial accounting and
reporting for acquired goodwill and other intangible assets. Under
SFAS No. 142, goodwill and some intangible assets will no longer be
amortized, but rather reviewed for impairment on a periodic basis. As
of January 1, 2002 the Company adopted the provisions of SFAS No. 142.
Therefore, goodwill and certain identifiable intangible assets with
indefinite lives have not been amortized and will be reviewed for
impairment on an annual basis.
In August 2001, the FASB issued SFAS No. 143, "Accounting for Asset
Retirement Obligations." This standard requires entities to record the
fair value of a liability for an asset retirement obligation in the
period in which it is incurred. When the liability is initially
recorded, the entity capitalizes a cost by increasing the carrying
amount of the related long-lived asset. Over time the liability is
accreted to its present value each period and the capitalized cost is
depreciated over the useful life of the related asset. Upon settlement
of the liability, an entity either settles the obligation for its
recorded amount or incurs a gain or loss upon settlement. The standard
is effective for fiscal years beginning after June 15, 2002. The
adoption of SFAS No. 143 is not expected to have a material impact on
the Company's financial statements.
In October 2001, the FASB issued SFAS No. 144, "Accounting for the
Impairment or Disposal of Long-Lived Assets." SFAS No. 144 replaces
SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and
for Long-Lived Assets to be Disposed Of." SFAS No. 144 requires that
long-lived assets be measured at the lower of carrying amount or fair
value less cost to sell, whether reported in continuing operations or
in discontinued operations. Therefore, discontinued operations will no
longer be measured at net realizable value or include amounts for
operating losses that have not yet occurred. SFAS No. 144 also
broadens the reporting of discontinued operations to include all
components of an entity with operations that can be distinguished from
the rest of the entity and that will be eliminated from the ongoing
operations of the entity in a disposal transaction. The provisions of
SFAS No. 144 are effective for financial statements issued for fiscal
years beginning after December 15, 2001. As of January 1, 2002 the
Company adopted the provisions of SFAS No. 144. The adoption of SFAS
No. 144 did not have a significant impact on the Company's financial
statements.
In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB
Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and
Technical Corrections." SFAS No. 145, among other things, rescinds
SFAS No. 4, which required all gains and losses from the
extinguishment of debt to be classified as an extraordinary item and
amends SFAS No. 13 to require that certain lease modifications that
have economic effects similar to sale-leaseback transactions be
accounted for in the same manner as sale-leaseback transactions. The
rescission of SFAS No. 4 is effective for fiscal years beginning after
May 15, 2002. The remainder of the statement is generally effective
for transactions occurring after May 15, 2002 with earlier application
encouraged. The Company does not expect the adoption of SFAS No. 145
to have a material impact on its consolidated financial statements.
In June 2002, the FASB issued SFAS No. 146, "Accounting for Exit or
Disposal Activities." This statement addresses the recognition,
measurement and reporting of costs that are associated with exit and
disposal activities. This statement includes the restructuring
activities that are currently accounted for pursuant to the guidance
set forth in EITF 94-3, "Liability Recognition for Certain Employee
Termination Benefits and other Costs to exit an Activity (including
Certain Costs Incurred in a Restructuring)," costs related to
terminating a contract that is not a capital lease and one-time
benefit arrangements received by employees who are involuntarily
terminated- nullifying the guidance under EITF 94-3. Under SFAS No.
146 the cost associated with an exit or disposal activity is
recognized in the periods in which it is incurred rather than at the
date the company committed to the exit plan. This statement is
effective for exit or disposal activities initiated after December 31,
2002 with earlier application encouraged. The Company does not believe
that the adoption of SFAS No. 146 will have a material effect on its
consolidated financial statements.
33
In November 2002, the FASB issued Financial Interpretation ("FIN") 45,
"Guarantor's Accounting and Disclosure Requirements for Guarantees,
Including Indirect Guarantees of Indebtedness of Others." FIN 45
requires that the guarantor recognize, at the inception of certain
guarantees, a liability for the fair value of the obligation
undertaken in issuing such guarantee. FIN 45 also requires additional
disclosure requirements about the guarantor's obligations under
certain guarantees that it has issued. The initial recognition and
measurement provisions of this interpretation are applicable on a
prospective bas